8 November 2015 - Harvard Pilgrim Health Care has agreed to cover Amgen Inc.’s pricey new cholesterol drug in exchange for a discount, along with potential rebates if the treatment fails to meet performance targets.

For more details, go to: http://www.bostonglobe.com/business/2015/11/08/harvard-pilgrim-strikes-pay-for-performance-deal-for-cholesterol-drug/iGIV7rBie4K20HNbKORsPJ/story.html?